Recent Company News

• 11:38 PM ET Jul 02, 2026
  

  StreetAccount Summary - Hong Kong unusual volume traders

• 12:04 AM ET Jun 30, 2026
  

  Innovent Biologics, Lilly enter into commercialization agreement for Verzenios (abemaciclib) in mainland China (HK$79.15, -0.90)

• 05:08 PM ET Jun 29, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 11:39 AM ET Jun 29, 2026
  

  China announces preliminary results of 2026 NRDL adjustment, 557 passed for basic medical insurance, 54 passed for commercial insurance list

• 07:42 PM ET Jun 25, 2026
  

  MHRA accepts Eisai's marketing application for taletrectinib for treatment of NSCLC (¥3949.0000, 0)

• 08:04 PM ET Jun 21, 2026
  

  Innovent Biologics doses first patient in China pivotal phase III study of IBI3003 (HK$76.15, 0.00)

• 03:48 AM ET Jun 09, 2026
  

  StreetAccount Summary: Hong Kong Stocks reaching new 52-week highs/lows (50 total)

• 12:08 AM ET Jun 09, 2026
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (181 total)

• 04:57 AM ET Jun 08, 2026
  

  Innovent Biologics presents multiple clinical, preclinical results at 2026 ADA (HK$73.25, 0.00)

• 02:09 AM ET Jun 05, 2026
  

  StreetAccount Sector Summary - China Healthcare May Recap